Infinimmune
Facts
as of Nov 17, 2026Derived from human biology, engineered for human health. Infinimmune systematically surfaces and engineers the rare antibodies evolution has already proven in people and advances them into the clinic.
- Employees
- 51-200estimated range
- Website
- infinimmune.com
These are the key facts about Infinimmune on Alion as of Nov 17, 2026. It has raised $87M in 2 funding rounds. The latest round is Venture - Series Unknown of $75M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Financials
Funding rounds, investors and revenue on record.
$87MTotal raised
Venture - Series UnknownLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
$75M
2022
$12M
Sources: funding announcements, grant and company registers
Milestones
Aug 11
Raised a round Venture round $75M
Apr 27
Dec 19, 2023
Dec 6, 2022
Raised a round Seed $12M
Dec 2021
Website went live first capture in the Wayback Machine
Each milestone is dated by its source: registers, filings, the press
Newsroom
top 6%Web presenceof 133.2M domains by links, Common Crawl
Aug 122026
News · Pulse 2.0
Infinimmune has raised $75 million in Series A financing to advance a pipeline of fully human antibody therapeutics for atopic dermatitis and other inflammatory diseases. The rou…
Aug 122026
News · MedCity News
Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead program…
Aug 112026
Apr 272026
News · YahooFinance
ALAMEDA, Calif., April 27, 2026--Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy
Mar 312026
News · reuters.com
Mar 312026
News · fiercebiotech.com
Sources: the outlets named on each headline, each story once
